Ribavirin (ICN-1229)

别名: NSC-163039, RTCA, Tribavirin 中文名称：利巴韦林

目录号：S2504 Purity: 99.89%

Ribavirin (NSC-163039, ICN-1229, RTCA, Tribavirin)是一种抗病毒剂，用于治疗重症RSV感染，丙型肝炎病毒感染和其他病毒感染。

Ribavirin (ICN-1229) Chemical Structure

CAS: 36791-04-5

规格	价格	库存
10mM (1mL in DMSO)	738.91	现货
100mg	574.27	现货
1g	3030.3	现货
更大包装有超大折扣
400-668-6834 info@selleck.cn

产品质控

批次：纯度： 99.89%

99.89

Ribavirin (ICN-1229)相关产品

相关产品	Moroxydine HCl Aloperine GS-441524 Oleanolic Acid NGI-1 Lapachol Saikosaponin B2 Harringtonine U18666A	点击展开
相关化合物库	抗感染化合物库抗生素化合物库抗病毒化合物库抗寄生虫药物库肠道微生物代谢物库	点击展开

细胞实验数据示例

细胞系	实验类型	给药浓度	孵育时间	活性描述	文献信息
human KB cells	Function assay	1-1000 μg/ml	72 h	Antiviral activity against Rhinovirus type 13 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect at 1 to 1000 ug/ml after 72 hrs	211234
MDCK cells	Function assay		3 days	Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis, EC50=0.094 μM	23117173
mouse L1210 cells	Function assay		20-60 mins	Inhibition of IMPDH in mouse L1210 cells assessed as formation of [2,8-3H]hypoxanthine from [2,8-3H]IMP after 20 to 60 mins, IC50=1 μM	22555152
human CEM cells	Function assay		20-60 mins	Inhibition of IMPDH in human CEM cells assessed as formation of [2,8-3H]hypoxanthine from [2,8-3H]IMP after 20 to 60 mins, IC50=1 μM	22555152
MDCK cells	Function assay		36 h	Antiinfluenza activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 36 hrs, IC50=1.9 μM	22341943
MDBK cells	Function assay		2 days	Antiviral activity against Bovine viral diarrhea virus 1-NADL ATCC VR534 infected in MDBK cells assessed as reduction of viral cytopathic effect after 2 days bt MTS assay, EC50=4.6 μM	22944333
african green monkey Vero cells	Function assay		5 days	Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay, EC50=7 μM	20359898
HEL cells	Function assay		2-3 days	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay, EC50=10 μM	20034711
HEK293 cells	Function assay		24 h	Inhibition of influenza A virus RNA-dependent RNA polymerase expressed in HEK293 cells after 24 hrs by dual luciferase reporter gene assay, EC50=15 μM	24313730
human BE(2)-C cells	Function assay		18-20 h	Antiviral activity against Western equine encephalomyelitis virus infected in human BE(2)-C cells assessed as inhibition of viral RNA replication after 18 to 20 hrs by luciferase reporter gene assay, IC50=16 μM	24151954
human MT4 cells	Cytotoxic assay		96 h	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay, CC50=31 μM	19482481
human HuH7 cells	Cytotoxic assay		3 days	Cytotoxicity against human HuH7 cells infected with HCV1b after 3 days by MTS assay, CC50=32 μM	22100256
human KB cells	Function assay		72 h	Antiviral activity against Rhinovirus type 13 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs relative to control	722730
E6SM cell lines	Function assay			Effective concentration required to inhibit Herpes simplex virus-1(HSV-1) / thymine kinase deficient (TK-)B2006 / VMW1837 induced cytopathicity by 50% in E6SM cell lines, EC50=0.005 μM	11495586
BHK21 cell line	Function assay			Inhibition of West Nile virus VLP replicon in BHK21 cell line, EC50=1.1 μM	16539402
HeLa cell	Function assay			Effective concentration required to inhibit respiratory synaptial(RSV) virus-induced cytopathicity by 50% in HeLa cell lines, EC50=1.5 μM	11495586
human HuH7-J20 cells	Function assay			Antiviral activity against HCV JFH1 infected in human HuH7-J20 cells assessed as inhibition of viral life cycle by measuring secreted alkaline phosphatase level preincubated with cells for 1 hr followed by viral inoculation for 3 hrs measured at 72 hrs, EC50=30.4 μM	26428870
点击查看更多细胞系数据

生物活性

产品描述	Ribavirin (NSC-163039, ICN-1229, RTCA, Tribavirin)是一种抗病毒剂，用于治疗重症RSV感染，丙型肝炎病毒感染和其他病毒感染。

体外研究(In Vitro)
体外研究活性	Ribavirin显著降低了亚基因组复制子转染细胞的复制系统的效率，尽管Ribavirin对HCV复制的水平几乎没有影响。Ribavirin增加丙型肝炎病毒的突变频率，NS5A编码区的突变率最高。Ribavirin增强TH1，同时抑制T2细胞因子产生刺激的T细胞。^[1] Ribavirin显示了抗病毒活性，抗多种RNA病毒，并结合使用α-干扰素来治疗丙型肝炎病毒感染。Ribavirin减少感染的脊髓灰质炎病毒的产生，少到细胞培养物的0.00001％。 ^[2] Ribavirin的抗病毒活性是通过病毒的遗传物质的致死突变直接作用。^[3] Ribavirin在生理浓度（高达500毫克/毫升）显着降低病毒引起的巨噬细胞的活化。Ribavirin抑制Th2细胞产生IL-4，而这并不会抹杀Th1细胞产生IFN-γ。^[4] Ribavirin在体外表现出对DNA和RNA病毒广泛的抗病毒活性。Ribavirin是一种细胞生长抑制剂，导致DNA，RNA和蛋白质合成的的减少。Ribavirin能诱导辅助性T细胞表型从从2型转变为1型。 ^[5]
实验图片	检测方法	检测指标	实验图片	PMID
	Western blot	p53 / p-p53 / p21 / Mdm2 EZH2 / p-ERK / ERK / p-eIF4E / eIF4E / p21 Cyclin D1 p-AKT / AKT / pBP1 / BP1		22962590
	Growth inhibition assay	Cell number		21415224

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
临床试验信息 (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT05940545	Recruiting	CCHF	Liverpool School of Tropical Medicine	July 12 2023	Phase 1\|Phase 2
NCT04283513	Not yet recruiting	Hemorrhagic Fever	U.S. Army Medical Research and Development Command	October 31 2022	Phase 2
NCT04335123	Completed	COVID-19	University of Kansas Medical Center	April 4 2020	Phase 1
NCT04285034	Completed	Lassa Fever	University of Oxford	November 26 2019	--
NCT03889106	Terminated	Lassa Fever	University of Oxford\|National Institute for Health Research United Kingdom\|Kenema Government Hospital\|London School of Hygiene and Tropical Medicine\|Public Health England	March 1 2019	--
NCT03585725	Terminated	Follicular Lymphoma\|Mantle Cell Lymphoma	Weill Medical College of Cornell University\|Memorial Sloan Kettering Cancer Center	September 26 2018	Early Phase 1

参考文献
[1] Feld JJ, et al. Nature, 2005, 436(7053), 967-972. [2] Crotty S, et al. Nat Med, 2000, 6(12), 1375-1379. [3] Crotty S, et al. Proc Natl Acad Sci U S A, 2001, 98(12), 6895-6900. [4] Ning Q, et al. J Immunol, 1998, 160(7), 3487-3493. [5] Graci JD et al. Rev Med Virol, 2006, 16(1), 37-48. + 展开

参考文献

+ 展开

化学信息&溶解度

分子量	244.20864	分子式	C₈H₁₂N₄O₅
CAS号	36791-04-5	SDF	Download Ribavirin (ICN-1229) SDF
Smiles	C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N
储存条件(自收到货起)	3年-20°C粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1年-80°C溶于溶剂
储存条件(自收到货起)	3年-20°C粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1个月-20°C溶于溶剂

体外溶解度
批次：

DMSO : 49 mg/mL ( (200.64 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Water : 49 mg/mL (200.64 mM)

Ethanol : Insoluble

DMSO : 48 mg/mL ( (196.55 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Water : 48 mg/mL (196.55 mM)

Ethanol : Insoluble

DMSO : 49 mg/mL ( (200.64 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Water : 49 mg/mL (200.64 mM)

Ethanol : Insoluble

摩尔浓度计算器

体内溶解度
批次：

现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂

动物体内配方计算器

实验计算

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×

稀释计算器分子量计算器

动物体内配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 μL 动物数量只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

计算结果：

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH₂O，混匀澄清。

体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。

注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

* 必填项

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):